Explore company profiles, quarterly results, announcements and ownership disclosures.
Loading the company view…
Marksans Pharma Limited (NSE: MARKSANS), ISIN INE750C01026 — earnings, PEAD surprise, concall summary, Walk-the-Talk management consistency, SAST and insider filings, and the EquiSense Score (ECS), all in plain English on EquiSense.
MARKSANS last traded at ₹308.65 (+1.63%), with a 52-week range of ₹155.00 to ₹350.95 (as of 6 Nov 2026).
Shareholding as of Sep 2026: promoters 43.87%, FIIs 19.06%, DIIs 5.54%, mutual funds 3.72%.
EquiSense Score (ECS): 78/100.
Data sourced from NSE and BSE filings. Educational — not investment advice.